Monday, September 20, 2010 7:28:34 AM
Ecology Coatings Appoints Orchard, Ramsey and Rempinski to its Board of Directors
WARREN, Mich., Sept 14, 2010 -- Ecology Coatings, Inc. (OTC Bulletin Board: ECOC), a leader in the discovery and development of nanotechnology-enabled, ultraviolet-curable advanced coatings, today announced that James Orchard, Sally Judith Weine Ramsey and Daniel Rempinski have been appointed to its Board of Directors.
James Orchard is the CEO of Mark IV Industries, a privately held, leading global diversified manufacturer of highly engineered systems and components for vehicles, transportation infrastructure and equipment. Mr. Orchard has an extensive background in the automotive industry where he held the positions of COO of Noble International and President of Faurecia, a global player the automotive industry. Mr. Orchard holds a B.S. in Marketing and Business Operations from Indiana University.
Sally Judith Weine Ramsey, the founder of Ecology Coatings, is Ecology's Vice President of New Product Development and chief chemist.Ms. Ramsey has been instrumental in the creation of the company's UV technology, patents and intellectual property. She is a graduate of the Bronx School of Science and holds a B.A. in Chemistry with honors from Hiram College.
Daniel Rempinski has been the Controller at the SmithGroup, Inc. since 2000. SmithGroup, Inc. owns companies in the architecture, engineering, consulting and construction industries. Mr. Rempinski holds a B.A. in Accounting from Wayne State University and a Masters in Finance from Walsh College.
Recent ABVC News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 01:27:45 PM
- AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share • GlobeNewswire Inc. • 04/18/2024 01:25:00 PM
- ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M • GlobeNewswire Inc. • 04/17/2024 01:00:00 PM
- ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M • GlobeNewswire Inc. • 04/10/2024 12:30:00 PM
- ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M • GlobeNewswire Inc. • 03/26/2024 12:30:00 PM
- AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million Dollars • GlobeNewswire Inc. • 03/21/2024 12:30:00 PM
- ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine • GlobeNewswire Inc. • 03/19/2024 12:30:00 PM
- ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update • GlobeNewswire Inc. • 03/14/2024 01:30:31 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 02/29/2024 09:32:35 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 02/29/2024 09:31:06 PM
- ABVC's New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion Dollars • GlobeNewswire Inc. • 02/27/2024 01:30:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/16/2024 10:04:42 PM
- ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues • GlobeNewswire Inc. • 02/15/2024 01:30:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 12:59:14 AM
- ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD) • GlobeNewswire Inc. • 02/12/2024 01:30:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/09/2024 10:04:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 02:30:48 PM
- ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share • GlobeNewswire Inc. • 02/08/2024 02:17:05 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 01/17/2024 10:01:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 10:00:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 09:30:12 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 01/12/2024 10:01:27 PM
- ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees • GlobeNewswire Inc. • 01/03/2024 12:24:57 PM
- ABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study • GlobeNewswire Inc. • 12/07/2023 01:30:00 PM
- ABVC BioPharma Shares Insights from Dr. Scott Irwin of Cedars-Sinai Medical Center over Depression in Cancer Patients Clinical Trials • GlobeNewswire Inc. • 12/05/2023 01:30:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM